In patients with chronic cerebral ischemia, laboratory and clinical efficacy of cerebrolysin with mexidol ranked lowest of three paired drug combinations, below actovegin with cereton and emoxipine with piracetam.
In plain wordsIn patients with chronic cerebral ischemia, cerebrolysin with mexidol had the lowest efficacy of three drug pairs, below actovegin with cereton and emoxipine with piracetam.
- Peptide
- Cerebrolysin
- Outcome
- DecreaseCombined laboratory and clinical efficacy ranking of drug combinations
- Study
n = 57
- Comparator
- Actovegin with cereton; emoxipine with piracetam
- Outcome group
- Overall treatment effect · Whole body
Source sentences
Laboratory and clinical efficacy of the combinations of neuroprotective and antioxidant drugs in DE reduced in the following order: actovegin and cereton → emoxipine and piracetam → cerebrolysin and mexidol.
1 context sentence(design, population, supporting numbers)
Authors analyzed the results of treatment of 57 patients with DE, stage II, comorbid to hypertension, stage II, which were divided into 3 groups that received comprehensive basic and advanced therapy with paired combinations of neuroprotective and antioxidant drugs.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.